FDA-approved product exists

Mecasermin

Also known as: Recombinant human IGF-1

FDA-approved

Mecasermin has FDA-approved prescription products (INCRELEX (BLA021839)). Mecasermin is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 40 registered ClinicalTrials.gov studies cite Mecasermin (25 completed, 8 terminated, 4 recruiting, 1 not yet recruiting, 1 unknown, 1 withdrawn); registration is not evidence of approval, efficacy, or safety. CompoundedGuide is verifying compounding status, safety signals, and current evidence. This is not medical advice.

What we've verified

Product status: FDA-approved: INCRELEX (BLA021839)
Still checking: Compounding status, shortage status, safety signals

Verified sources

openFDA Drugs@FDA P0 · retrieved 2026-07-25
503B Bulks List and Interim Categories P0 · retrieved 2026-07-25
ClinicalTrials.gov API v2 P0 · retrieved 2026-07-25

Research and evidence

FDA-approved product exists cite Mecasermin. Registration is not evidence of approval, efficacy, or safety.

Browse every trial and publication for Mecasermin →

For developers

JSON record Markdown Source packet